^
    Back
    Association details:
    Biomarker:FOLR1 positive
    Cancer:Ovarian Cancer
    Drug:Elahere (mirvetuximab soravtansine-gynx) (Microtubule inhibitor, Folate receptor 1-targeted antibody-drug conjugate)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: A1 - Approval
    Source:
    FDA
    Published date:
    11/14/2022
    Excerpt:
    ELAHERE is a folate receptor alpha (FRα)-directed antibody and microtubule inhibitor conjugate indicated for the treatment of adult patients with FRα positive, platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer, who have received one to three prior systemic treatment regimens.
    Test:
    VENTANA FOLR1 RxDx Assay
    Evidence Level:
    Sensitive: B - Late Trials
    Source:
    N Engl J Med
    Title:

    Mirvetuximab Soravtansine in FRα-Positive, Platinum-Resistant Ovarian Cancer

    Published date:
    12/07/2023
    Excerpt:
    Among participants with platinum-resistant, FRα-positive ovarian cancer, treatment with MIRV showed a significant benefit over chemotherapy with respect to progression-free and overall survival and objective response.
    DOI:
    10.1056/NEJMoa2309169
    Trial ID:
    MIRASOL
    Evidence Level:
    Sensitive: B - Late Trials
    Source:
    Immunogen Press Release
    Title:

    ELAHERE® Shows Overall and Progression-Free Survival Benefit Regardless of Prior PARPi Exposure or Prior Lines of Therapy in FRα-Positive Platinum-Resistant Ovarian Cancer

    Published date:
    09/28/2023
    Excerpt:
    ImmunoGen Inc...announced findings from two subset analyses of the Phase 3 confirmatory MIRASOL trial (GOG 3045/ENGOT OV-55) evaluating the safety and efficacy of ELAHERE® (mirvetuximab soravtansine-gynx) compared to chemotherapy in patients with folate receptor alpha (FRα)-positive platinum-resistant ovarian cancer (PROC)...ELAHERE demonstrated clinically meaningful improvement in PFS and ORR by investigator assessment and in OS compared to IC chemotherapy, regardless of prior PARPi exposure.
    Evidence Level:
    Sensitive: B - Late Trials
    Source:
    Immunogen Press Release
    Title:

    ELAHERE® Demonstrates Overall Survival Benefit in the Phase 3 MIRASOL Trial in Patients with FRα-Positive Platinum-Resistant Ovarian Cancer

    Published date:
    05/03/2023
    Excerpt:
    ImmunoGen Inc...announced positive top-line data from the Phase 3 confirmatory MIRASOL trial (GOG 3045/ENGOT OV-55) evaluating the safety and efficacy of ELAHERE® (mirvetuximab soravtansine-gynx) compared to chemotherapy in patients with folate receptor alpha (FRα)-positive platinum-resistant ovarian cancer who have received one to three prior lines of therapy...ELAHERE demonstrated a statistically significant and clinically meaningful improvement in PFS by investigator assessment compared to IC chemotherapy, with a hazard ratio of 0.65 (p<0.0001)...
    Trial ID:
    MIRASOL
    Test:
    VENTANA FOLR1 RxDx Assay
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    New
    Source:
    clinicaltrials.gov
    Title:

    A Study of Mirvetuximab Soravtansine vs. Investigator's Choice of Chemotherapy in Women With Folate Receptor (FR) Alpha Positive Advanced Epithelial Ovarian Cancer (EOC), Primary Peritoneal or Fallopian Tube Cancer

    Excerpt:
    ...- Participants must have folate receptor alpha positive tumor expression as defined in the protocol...
    Trial ID:
    FORWARD I
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    Expert Rev Clin Pharmacol
    Title:

    The efficacy and toxicity of mirvetuximab soravtansine, a novel antibody-drug conjugate, in the treatment of advanced or recurrent ovarian cancer: a meta-analysis

    Published date:
    09/28/2023
    Excerpt:
    ORR of MIRV was 34.2% (95% confidence interval [CI] 25.0-43.5), and PFS was 5.82 months (95%CI 4.47 7.18)...MIRV has definite efficacy and good safety as a novel choice for second-line and above treatment of advanced or recurrent FRα positive ovarian cancer.
    DOI:
    10.1080/17512433.2023.2262673